These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 22721367)

  • 21. [Management of spasticity in children with cerebral palsy].
    Matthews DJ; Balaban B
    Acta Orthop Traumatol Turc; 2009; 43(2):81-6. PubMed ID: 19448346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug treatments for spasticity.
    Yelnik AP; Simon O; Bensmail D; Chaleat-Valayer E; Decq P; Dehail P; Quentin V; Marque P; Parratte B; Pellas F; Rousseaux M; Trocello JM; Uzzan M; Dumarcet N;
    Ann Phys Rehabil Med; 2009 Dec; 52(10):746-56. PubMed ID: 19892619
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical outcome and complications of intrathecal baclofen pump in multiple sclerosis patients: a retrospective study.
    Khan AA; Birks-Agnew I; Bullock P; Rushton D
    NeuroRehabilitation; 2010; 27(2):117-20. PubMed ID: 20871140
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacotherapy of spasticity: oral medications and intrathecal baclofen.
    Krach LE
    J Child Neurol; 2001 Jan; 16(1):31-6. PubMed ID: 11225954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam.
    Groves L; Shellenberger MK; Davis CS
    Adv Ther; 1998; 15(4):241-51. PubMed ID: 10186943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of intrathecal baclofen, botulinum toxin type A and a rehabilitation programme on locomotor function after spinal cord injury: a case report.
    Santamato A; Panza F; Ranieri M; Amoruso MT; Amoruso L; Frisardi V; Solfrizzi V; Fiore P
    J Rehabil Med; 2010 Oct; 42(9):891-4. PubMed ID: 20878052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The incidence and management of tolerance in intrathecal baclofen therapy.
    Heetla HW; Staal MJ; Kliphuis C; van Laar T
    Spinal Cord; 2009 Oct; 47(10):751-6. PubMed ID: 19333246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Optimized therapy of spastic syndrome by combination intrathecal baclofen with botulinum toxin].
    Vogt T; Urban PP
    Nervenarzt; 2000 Dec; 71(12):1007-11. PubMed ID: 11139983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity.
    Dai AI; Aksoy SN; Demiryürek AT
    J Child Neurol; 2016 Feb; 31(2):184-9. PubMed ID: 25999301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Botulinum toxin type A with oral baclofen versus oral tizanidine: a nonrandomized pilot comparison in patients with cerebral palsy and spastic equinus foot deformity.
    Dai AI; Wasay M; Awan S
    J Child Neurol; 2008 Dec; 23(12):1464-6. PubMed ID: 19073853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An approach to switching patients from baclofen to tizanidine.
    Brenner R; Hyman N; Knobler R; O'Brien M; Stephan T
    Hosp Med; 1998 Oct; 59(10):778-82. PubMed ID: 9850294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis.
    Eyssette M; Rohmer F; Serratrice G; Warter JM; Boisson D
    Curr Med Res Opin; 1988; 10(10):699-708. PubMed ID: 3286128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of severe spasticity treatment with intrathecal Baclofen in multiple sclerosis patients: Long term follow-up.
    Stampacchia G; Gerini A; Mazzoleni S
    NeuroRehabilitation; 2016 Apr; 38(4):385-93. PubMed ID: 27061166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
    Wissel J; Entner T
    Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intrathecal baclofen in multiple sclerosis.
    Stevenson VL
    Eur Neurol; 2014; 72 Suppl 1():32-4. PubMed ID: 25278123
    [No Abstract]   [Full Text] [Related]  

  • 36. Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients.
    Ben Smail D; Peskine A; Roche N; Mailhan L; Thiébaut I; Bussel B
    Mult Scler; 2006 Feb; 12(1):101-3. PubMed ID: 16459726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacotherapy of spasticity in children with cerebral palsy.
    Chung CY; Chen CL; Wong AM
    J Formos Med Assoc; 2011 Apr; 110(4):215-22. PubMed ID: 21540003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group.
    Neurology; 1994 Nov; 44(11 Suppl 9):S70-8. PubMed ID: 7970014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined treatment with BTX-A and ITB for spasticity: case report.
    Gill CE; Andrade EO; Blair CR; Taylor HM; Charles D
    Tenn Med; 2007 Oct; 100(10):41-2, 44. PubMed ID: 17966716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatments for spasticity and pain in multiple sclerosis: a systematic review.
    Beard S; Hunn A; Wight J
    Health Technol Assess; 2003; 7(40):iii, ix-x, 1-111. PubMed ID: 14636486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.